Belgium

Reimbursed Care Access

Belgium permits licensed psychedelic-derived medicines only within established regulatory pathways (e.g., esketamine nasal spray). Classical/recreational psychedelics (psilocybin, MDMA, DMT family, mescaline, ibogaine, 2C‑X, ayahuasca) remain controlled and have no routine reimbursed medical access outside authorised clinical trials. Off‑label medical use (for example ketamine infusions) can occur in clinical practice under the clinician’s responsibility but is not part of routine public reimbursement except where standard reimbursement rules for hospital/anaesthesia care apply.